Corcept Therapeutics - CORT Stock Forecast, Price & News

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Jefferies Financial Group raised Corcept Therapeutics from a "hold" rating to a "buy" rating and lifted their price target for the stock from $21.00 to $35.00 in a research note on Wednesday, July 27th. Truist Financial cut shares of Corcept Therapeutics to a "hold" rating in a research report on Tuesday. StockNews.com lowered shares of Corcept Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday. Finally, HC Wainwright increased their price objective on shares of Corcept Therapeutics from $29.00 to $33.00 and gave the company a "buy" rating in a report on Thursday, August 4th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $32.00.

Corcept Therapeutics Stock Down 1.3 %

Shares of Corcept Therapeutics stock traded down $0.37 during mid-day trading on Tuesday, hitting $27.98. The stock had a trading volume of 10,325 shares, compared to its average volume of 673,888. Corcept Therapeutics has a 12-month low of $15.82 and a 12-month high of $29.93. The firm has a market cap of $3.00 billion, a P/E ratio of 29.98, a price-to-earnings-growth ratio of 2.89 and a beta of 0.51. The firm has a 50-day moving average of $24.86 and a two-hundred day moving average of $22.94.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, insider Sean Maduck sold 25,000 shares of the stock in a transaction dated Monday, July 18th. The shares were sold at an average price of $27.37, for a total transaction of $684,250.00. Following the completion of the transaction, the insider now owns 40,024 shares of the company's stock, valued at $1,095,456.88. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Corcept Therapeutics news, CEO Joseph K. Belanoff sold 279,908 shares of Corcept Therapeutics stock in a transaction dated Wednesday, July 6th. The stock was sold at an average price of $26.27, for a total value of $7,353,183.16. Following the completion of the transaction, the chief executive officer now directly owns 2,538,218 shares of the company's stock, valued at approximately $66,678,986.86. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Sean Maduck sold 25,000 shares of the firm's stock in a transaction that occurred on Monday, July 18th. The shares were sold at an average price of $27.37, for a total transaction of $684,250.00. Following the completion of the transaction, the insider now directly owns 40,024 shares of the company's stock, valued at approximately $1,095,456.88. The disclosure for this sale can be found here. In the last ninety days, insiders sold 384,780 shares of company stock worth $9,889,303. 16.50% of the stock is currently owned by company insiders.